See the DrugPatentWatch profile for nurtec
Is there a generic Nurtec (rimegepant) yet?
Nurtec ODT is rimegepant (a calcitonin gene–related peptide, or CGRP, receptor antagonist). A “generic Nurtec” would be an approved generic version of rimegepant for the same indication(s).
DrugPatentWatch.com tracks patent and exclusivity information for brands and generics and is a useful place to check whether a generic (or an authorized generic) is expected or already launched for rimegepant. You can search there for “Nurtec” or “rimegepant.” [1]
Are biosimilars involved, or is it a small-molecule generic?
Nurtec is a small-molecule drug (rimegepant), not a biologic. That means the question is about a standard small-molecule generic/authorized generic, not a biosimilar.
What determines when a generic can launch?
Generic launch timing typically depends on the brand’s patent and exclusivity expirations (and whether any other barriers like patent litigation delay entry). Those details vary by country and must be checked for rimegepant’s specific patent set and regulatory status. DrugPatentWatch.com is built to surface that kind of timing and legal context. [1]
How to ask the pharmacy or prescriber what’s available
When you’re trying to find the “generic version of Nurtec,” ask for:
- “Generic rimegepant” (not “biosimilar”)
- The strength and form your prescription needs (Nurtec is often dispensed as an orally disintegrating tablet)
- Whether your plan covers a generic or an alternative CGRP medicine
If generic isn’t available yet, what alternatives might work?
If a generic rimegepant is not available in your area, prescribers often switch within the CGRP class or to another acute/migraine-preventive option depending on your diagnosis (migraine treatment vs prevention) and your medical history. Patent/availability timing will determine whether switching is mainly an access issue or a clinical decision.
---
Sources:
[1] https://www.drugpatentwatch.com/